Being south Asian or centrally obese may be associated with an increased risk of inflammation. The investigators are seeking to investigate whether this is the case by recruiting white European and south Asian men who are lean or have central obesity. Further, the investigators wish to investigate whether physical activity influences the associations.
Central obesity is associated with an increased risk of cardiovascular disease. Further, south Asians have been shown to be at an increased risk of cardiovascular disease compared to white Europeans. Cardiovascular disease is underpinned by inflammation. Evidence suggests that people with obesity have a more pro-inflammatory and pro-migratory monocyte profile compared with individuals who are lean. The excessive monocyte migration contributes to metabolic dysfunction over time, increasing the risk of chronic disease. However, there is no evidence in south Asians. One modifiable risk factor which may be able to influence this is physical inactivity, with higher levels of physical activity being associated with reduced inflammation. However, although south Asians are more at risk of cardiovascular disease than white Europeans, evidence suggests south Asians are also less physically active than white Europeans. The investigators are looking to recruit south Asian and white European men who are lean or have central obesity to investigate 1) is there an association between ethnicity and the tethering and migration of pro-inflammatory monocytes? 2) is there an association between central obesity and the tethering and migration of pro-inflammatory monocytes, and is there an interaction with ethnicity? 3) do higher levels of physical activity influence the tethering and migration of pro-inflammatory monocytes, and is this influenced by ethnicity or central obesity? To investigate this, the investigators are looking to recruit south Asian and white European men who are either centrally obese or lean. The investigators require 1 blood sample and the participants to wear an activity monitor for 7 days. Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood sample. Then, the investigators will quantify the migratory capacity of PBMCs to a fixed chemokine gradient over time. Further, the investigators will phenotype the monocytes to indicate the characteristics of the monocytes that migrate towards the chemokine mix. The activity monitor will quantify habitual physical activity, which will be used in the statistical analyses to investigate whether physical activity may influence the response. It is important to investigate as it will further scientific knowledge on the underpinnings of chronic disease and enable a better understanding on the role of physical activity to potentially reduce the risk.
7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
National Centre for Sport and Exercise Medicine
Loughborough, United Kingdom
Concentrations of classical monocytes.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentrations of intermediate monocytes.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentrations of non-classical monocytes.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentrations of CCR2+ monocytes.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentrations of CCR2+ classical monocytes.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentrations of CCR5+ monocytes.
Determined via flow cytometry. Presented as cells/uL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of monocytes that migrated.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Study Type
OBSERVATIONAL
Enrollment
40
Number of classical monocytes that migrated.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of intermediate monocytes that migrated.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of non-classical monocytes that migrated.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of CCR2+ monocytes that migrated.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of CCR2+ classical monocytes that migrated.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of CCR5+ monocytes that migrated.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of monocytes that tethered.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of classical monocytes that tethered.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of intermediate monocytes that tethered.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of non-classical monocytes that tethered.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of CCR2+ monocytes that tethered.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of CCR2+ classical monocytes that tethered.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Number of CCR5+ monocytes that tethered.
Determined via flow cytometry. Presented as number of cells.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
CCR2+ receptor expression.
Determined via flow cytometry.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
CCR5+ receptor expression.
Determined via flow cytometry.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentration of total cholesterol.
Fasted concentration of total cholesterol. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentration of high-density lipoprotein cholesterol (HDL).
Fasted concentration of high-density lipoprotein cholesterol. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentration of low-density lipoprotein cholesterol (LDL).
Fasted concentration of low-density lipoprotein cholesterol. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentration of triacylglycerol.
Fasted concentration of triacylglycerol. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentration of glucose.
Fasted concentration of glucose. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentration of c-reactive protein.
Fasted concentration of c-reactive protein. Presented as mg/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentration of interleukin-6.
Fasted concentration of interleukin-6. Presented as pg/mL.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Concentration of non-esterified free fatty acids.
Fasted concentration of non-esterified free fatty acids. Presented as mmol/L.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Body fat percentage.
Body fat percentage determined via bioelectrical impedance analysis. Presented as percentage.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Lean mass.
Determined via bioelectrical impedance analysis. Presented in kilograms.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Waist circumference
Waist circumference. Presented as centimetres.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Systolic blood pressure.
Presented as mmHg.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Diastolic blood pressure.
Presented as mmHg.
Time frame: The outcome will be measured as a single-time point assessment in a fasted state on day 1.
Light physical activity minutes per day.
Time spent participating in light physical activity. Presented as minutes per day.
Time frame: Over 7 days +/- the assessment day
Moderate-to-vigorous activity minutes per day.
Time spent participating in moderate-to-vigorous physical activity. Presented as minutes per day.
Time frame: Over 7 days +/- the assessment day
Daily steps.
Total daily steps. Presented as steps per day.
Time frame: Over 7 days +/- the assessment day